Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 1;3(2):79–82. doi: 10.1016/j.lrr.2014.06.001

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors

This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Fig. 3 — ABT-737 has an equally high cytotoxic efficacy in disseminated AML pLSCs. Bone marrow and peripheral blood-derived primary AML cells from 2 matching patients were cultured and treated and the percentage of surviving cells determined as described before. (A) Viability of bone marrow-derived and peripheral blood-derived overall AML population after exposure to ABT-737. (B) The percentage of CD34⁺/CD38⁻ cells within the surviving population of leukemic blasts in both bone marrow and peripheral blood-derived matching sample sets showing equal efficacy of ABT-737 compound against AML blasts and pLSCs. The % of pLSCs within live AML cell population was evaluated as a number of CD34⁺/CD38⁻-7AAD⁻ events. Different shapes indicate data-points corresponding to different patient samples. (Patients cross-referencing with Table 1: Patient 2 (■), Patient 4 (□)).